Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
826 stopped studies mapped to Malignant Female Reproductive System Neoplasm and descendants · 86% state a reason
Over the 826 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT04562298 | A Phase I Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of LCAR-M23,… | Phase 1 | terminated | Sep 24, 2020 | Shanghai East Hospital | Both the sponsors and collaborator are considering terminating the study. | Other (stated, no rule matched) |
| NCT02117817 | Phase I BKM120/Abraxane in Solid Tumors, Expansion Phase Recurrent Endometrial or Ovarian… | Phase 1 | withdrawn | Apr 21, 2014 | Rutgers, The State University of New Jersey | Research cancelled | Other (stated, no rule matched) |
| NCT03400956 | Assess Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids (ASTEROID 4) | Phase 3 | terminated | Jan 17, 2018 | Bayer | Due to a change in the development program, the study was closed prematurely. | Other (stated, no rule matched) |
| NCT03827993 | Improving Sexual Health in Gynecologic Cancer Patients | N/A | terminated | Feb 4, 2019 | Case Comprehensive Cancer Center | PI left institution | Investigator |
| NCT04941378 | OTL38 Injection (OTL38) for Intra-Operative Imaging of Folate Receptor Positive Ovarian… | Phase 1 | withdrawn | Jun 28, 2021 | Abramson Cancer Center at Penn Medicine | Due to sponsor request | Other (stated, no rule matched) |
| NCT03834571 | Testing the Addition of Paclitaxel and Carboplatin Given After Standard Chemotherapy and… | Phase 2 | withdrawn | Feb 8, 2019 | AIDS Malignancy Consortium | Not approved by CTEP | Other (stated, no rule matched) |
| NCT03382574 | Pilot Study of Denosumab in BRCA1/2 Mutation Carriers Scheduled for Risk-Reducing… | Early Phase 1 | terminated | Dec 26, 2017 | National Cancer Institute (NCI) | it was decided that due to lack of accrual on the trial, and low potential for accruing over the… | Enrollment / accrual |
| NCT03100006 | Phase Ib/IIa Trial to Evaluate Oregovomab and Nivolumab in Epithelial Cancer of Ovarian,…(ORION-01) | Phase 1 / Phase 2 | terminated | Apr 4, 2017 | National Cancer Centre, Singapore | The study had poor efficacy. | Efficacy / futility |
| NCT02900560 | Study of Pembrolizumab With or Without CC-486 in Patients With Platinum-resistant Ovarian… | Phase 2 | terminated | Sep 14, 2016 | Translational Research in Oncology | not stated | Not stated |
| NCT03077698 | An Endometrial Cancer Study for Women With Recurrent or Persistent Endometrial Cancer | Phase 2 | terminated | Mar 13, 2017 | Xenetic Biosciences, Inc. | The study was discontinued due to a change in development strategy and not due safety concern. | Safety / toxicity |
| NCT04230954 | Cabozantinib Plus Pembrolizumab for Recurrent, Persistent and/or Metastatic Cervical… | Phase 2 | terminated | Jan 18, 2020 | University of South Alabama | PI left institution | Investigator |
| NCT04178460 | A Study of Niraparib Combined With MGD013 in Patients With Advanced or Metastatic Solid… | Phase 1 | terminated | Nov 26, 2019 | Zai Lab (Shanghai) Co., Ltd. | This termination decision is a business decision and is not due to any safety concerns. | Safety / toxicity |
| NCT04806945 | A Phase III Study to Evaluate Efficacy and Safety of First-Line Treatment With HLX10 +… | Phase 3 | withdrawn | Mar 19, 2021 | Shanghai Henlius Biotech | The sponsor terminated the trial. | Other (stated, no rule matched) |
| NCT04630483 | Platelet-lymphocyte and Neutrophil-lymphocyte Ratio in Patients Undergoing Cancer Surgery | — | withdrawn | Nov 16, 2020 | Medipol University | No participants | Other (stated, no rule matched) |
| NCT04795596 | Secondary Cytoreductive Surgery in Platinum-resistant Recurrent Ovarian Cancers | Phase 2 / Phase 3 | withdrawn | Mar 12, 2021 | Menoufia University | Poor accrual | Enrollment / accrual |
| NCT03924245 | Olaparib and Entinostat in Patients With Recurrent, Platinum-Refractory, Resistant… | Phase 1 | terminated | Apr 23, 2019 | Vanderbilt-Ingram Cancer Center | Change in participant landscape and other treatment availability | Other (stated, no rule matched) |
| NCT03977311 | MR-Guided High-Intensity Focused Ultrasound in Conjunction With Radiation Therapy for the… | N/A | withdrawn | Jun 6, 2019 | Washington University School of Medicine | PI decided not to go forward with study. | Other (stated, no rule matched) |
| NCT04611139 | Pilot Trial of SP-2577 Plus Pembrolizumab in Select Gynecologic Cancers | Phase 1 | withdrawn | Nov 2, 2020 | HonorHealth Research Institute | Salarius discontinued support | Other (stated, no rule matched) |
| NCT03690739 | Evaluation of Symptom Benefit Rate of Trabectedin/PLD in Patients With Recurrent Ovarian… | Phase 3 | terminated | Oct 1, 2018 | AGO Research GmbH | Insufficient Recruitment | Enrollment / accrual |
| NCT01881451 | Imaging Tumor Hypoxia With 18F-EF5 PET in Recurrent or Metastatic Clear Cell Ovarian… | — | terminated | Jun 19, 2013 | British Columbia Cancer Agency | Due to slow accrual and access to the study drug. | Enrollment / accrual |
| NCT01485874 | Doxorubicin + BIBF 1120 in Patients for Ovarian Cancer | Phase 1 | terminated | Dec 6, 2011 | Hoosier Cancer Research Network | Funding withdrawn due to drug unavailability | Funding |
| NCT02628535 | Safety Study of MGD009 in B7-H3-expressing Tumors | Phase 1 | terminated | Dec 11, 2015 | MacroGenics | Business decision (not for safety reasons) | Safety / toxicity |
| NCT03324958 | VIrtual REality Glasses for the Enhancement of Acute BRACHYtherapy Tolerance for…(Vire-Brachy) | N/A | terminated | Oct 30, 2017 | Centre Hospitalier Universitaire de Saint Etienne | Enrollment difficulties | Enrollment / accrual |
| NCT04367467 | Effect of PARP Inhibitors on Glomerular Filtration Rate | — | terminated | Apr 29, 2020 | University of Pennsylvania | Due to constraints of COVID19, we were unable to recruit on-site for this study. | COVID-19 / pandemic |
| NCT03029611 | IGFBP-2 Vaccine and Combination Chemotherapy in Treating Patients With Stage III-IV… | Phase 2 | terminated | Jan 24, 2017 | University of Washington | Terminated due to lack of funding | Funding |
| NCT03905902 | DCVAC/OvCa and Standard of Care (SoC) in Relapsed Ovarian, Fallopian Tube, and Primary…(VITALIA) | Phase 3 | withdrawn | Apr 8, 2019 | SOTIO a.s. | Company decision | Sponsor / business decision |
| NCT01285102 | Chemoembolization Using Irinotecan in Treating Patients With Liver Metastases From… | Phase 1 | terminated | Jan 27, 2011 | Fox Chase Cancer Center | This study was closed early by the DSMB due to increased toxicity. | Safety / toxicity |
| NCT01018563 | An Open Label Extension Study of the Efficacy of MORAb-003 | Phase 2 | terminated | Nov 23, 2009 | Morphotek | Study was terminated by sponsor due to futile results in NCT00849667 study. | Other (stated, no rule matched) |
| NCT03945786 | Diagnostic Performance of Hybrid PET/MRI in the Staging of Endometrial Carcinoma | — | suspended | May 10, 2019 | Xuanwu Hospital, Beijing | Recuriting inclusion and exclusion criteria will be changed as COVID-19. | COVID-19 / pandemic |
| NCT01312389 | A Clinical Trial of Autologous Oxidized Tumor Cell Lysate Vaccine For Recurrent Ovarian,… | Phase 1 / Phase 2 | terminated | Mar 10, 2011 | Abramson Cancer Center at Penn Medicine | Did not meet criteria laid out in Phase 1 to continue to Phase 2 | Other (stated, no rule matched) |
| NCT03342417 | Combination of Nivolumab and Ipilimumab in Breast, Ovarian and Gastric Cancer Patients | Phase 2 | terminated | Nov 17, 2017 | ExcellaBio LLC | Slow patient accrual | Enrollment / accrual |
| NCT00900562 | Clinical Trial of PM00104 (Zalypsis®) in Patients With Advanced and/or Metastatic… | Phase 2 | terminated | May 13, 2009 | PharmaMar | Slow and poor recruitment. | Enrollment / accrual |
| NCT01035658 | Pazopanib/Doxil in Adv Relapsed Plat Sensitive or Resistant Ovarian, Fallopian or Primary… | Phase 1 / Phase 2 | terminated | Dec 21, 2009 | SCRI Development Innovations, LLC | Based on analyses in Phase I, the study did not advance to Phase II. | Other (stated, no rule matched) |
| NCT03328013 | Impact of HPV Vaccination to Catch up in the Emergence of Lesions of the Cervix(HPVAC) | — | terminated | Nov 1, 2017 | University Hospital, Brest | manager's decision | Other (stated, no rule matched) |
| NCT03634150 | Safety and Efficacy of IV Nerofe™ Followed by Doxorubicin, In Metastatic Ovarian Cancer… | Phase 1 / Phase 2 | withdrawn | Aug 16, 2018 | Immune System Key Ltd | Patients were screened but not enrolled | Enrollment / accrual |
| NCT02740114 | Wound Infiltration With Liposomal Bupivacaine vs. Standard Wound Infiltration With… | Phase 3 | terminated | Apr 15, 2016 | M.D. Anderson Cancer Center | Per PIs request | Other (stated, no rule matched) |
| NCT01902966 | Feasibility - Beta Adrenergic Blockade (BB) in Cervical Cancer (CX) | N/A | terminated | Jul 18, 2013 | M.D. Anderson Cancer Center | low accrual and lack of funding | Enrollment / accrual |
| NCT01170650 | Study for Women With Platinum Resistant Ovarian Cancer Evaluating EC145 in Combination…(PROCEED) | Phase 3 | terminated | Jul 27, 2010 | Endocyte | DSMB decision | Other (stated, no rule matched) |
| NCT03607955 | Paclitaxel + Carboplatin With AVB-S6-500 in Women With Stage III or IV Epithelial… | Phase 1 | withdrawn | Jul 31, 2018 | Washington University School of Medicine | Trial may move forward as an NCI-sponsored trial and not an investigator initiated trial. | Investigator |
| NCT03608618 | Intraperitoneal MCY-M11 (Mesothelin-targeting CAR) for Treatment of Advanced Ovarian… | Phase 1 | terminated | Aug 1, 2018 | MaxCyte, Inc. | Sponsor shift in focus | Other (stated, no rule matched) |
| NCT04099277 | A Study of LY3435151 in Participants With Solid Tumors | Phase 1 | terminated | Sep 23, 2019 | Eli Lilly and Company | Study terminated due to strategic business decision by Eli Lilly and Company. | Sponsor / business decision |
| NCT03933761 | Pamiparib in Fusion Positive, Reversion Negative High Grade Serous Ovarian Cancer or…(PRECISE) | Phase 2 | withdrawn | May 1, 2019 | Australia New Zealand Gynaecological Oncology Group | No eligible patient identified after 18 evaluable patients underwent pre-screening over a 2 year… | Other (stated, no rule matched) |
| NCT02127151 | A Parp Inhibitor (BMN 673) for Inoperable Advanced eNDometrial cAncer(PANDA) | Phase 2 | withdrawn | Apr 30, 2014 | University College, London | Withdrawal of Industry support for the study | Other (stated, no rule matched) |
| NCT03806049 | Trial Comparing Niraparib-bevacizumab-Dostarlimab and Niraparib-bevacizumab to Standard… | Phase 3 | withdrawn | Jan 16, 2019 | Nordic Society of Gynaecological Oncology - Clinical Trials Unit | Lack of financial support | Funding |
| NCT00911079 | Pilot Study of a Catheter-based Ultrasound Hyperthermia System | N/A | terminated | Jun 1, 2009 | University of California, San Francisco | Low Accrual | Enrollment / accrual |
| NCT00232713 | Uterine Fibroid Pregnancy Registry | — | terminated | Oct 5, 2005 | Syneos Health | not stated | Not stated |
| NCT00978874 | Fluorine F 18 EF5 PET/CT Imaging in Patients With Locally Advanced or… | N/A | terminated | Sep 17, 2009 | Abramson Cancer Center at Penn Medicine | The PI is no longer with our institution | Other (stated, no rule matched) |
| NCT00577317 | Flexitouch® Home Maintenance Therapy or Standard Home Maintenance Therapy in Treating… | Phase 3 | terminated | Dec 20, 2007 | Gynecologic Oncology Group | not stated | Not stated |
| NCT00582205 | Feasibility Trial of Intraperitoneal Chemotherapy for Ovarian, Fallopian Tube, and… | Phase 2 | terminated | Dec 28, 2007 | University of Oklahoma | Study completed per investigator. | Investigator |
| NCT03786107 | HER-Seq: A Blood-based Screening Study to Identify Patients With HER2 Mutations for… | — | terminated | Dec 24, 2018 | Puma Biotechnology, Inc. | The study was stopped early due to increased global access to genomic screening. It is no longer… | Other (stated, no rule matched) |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Aug 18, 2022source: clinicaltrials